UBS Group AG Sells 454,873 Shares of CorMedix Inc $CRMD
UBS Group AG significantly reduced its stake in CorMedix Inc. by selling 454,873 shares, cutting its holdings by 41.7% in the fourth quarter. Despite this, CorMedix reported strong quarterly earnings, beating analyst estimates with $0.43 EPS and 226.1% year-over-year revenue growth. Analyst sentiment remains positive, with a "Moderate Buy" consensus rating and an average price target of $15.00.
CRMD Q1 earnings beat on DefenCath momentum, guidance raised
CorMedix (CRMD) reported better-than-expected Q1 earnings, driven by strong sales of DefenCath. The company's net product sales reached $8.7 million, surpassing analyst estimates, prompting an upward revision of its full-year 2026 revenue guidance to $33-38 million. This positive performance and outlook reflect the successful commercial launch and growing adoption of DefenCath.
CorMedix: Long-Term Prospects Remain Poor Despite Q1 Beat (NASDAQ:CRMD)
CorMedix remains a "Sell" despite its Q1 outperformance, which is considered unsustainable due to non-recurring revenue and anticipated reimbursement challenges for DefenCath. The company faces an 80% sequential revenue decline for DefenCath post-TDAPA, and management's reaffirmation of 2027 guidance suggests no immediate rebound. Furthermore, delays in the TPN trial and weak Rezzayo data reduce pipeline potential, contributing to a cautious long-term outlook.
HC Wainwright Forecasts CorMedix's Q2 Earnings (NASDAQ:CRMD)
HC Wainwright has increased its Q2 2026 EPS estimate for CorMedix to $0.26 from $0.21, maintaining a "Buy" rating and a $13 price target. This upward revision follows CorMedix's strong Q1 performance, where the company surpassed analyst expectations with $0.43 EPS and a revenue increase of 226.1% year-over-year. Other analysts largely hold a positive view, with a "Moderate Buy" consensus and an average price target of $15 for the stock.
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And Phase III Results
CorMedix (CRMD) reported strong Q1 2026 results with US$127.43 million in revenue and US$38.6 million in net income, leading to a raised full-year 2026 net revenue guidance of US$325 million to US$345 million. This positive financial update, combined with favorable Phase III results for REZZAYO and progress in other pipeline programs, suggests a potential shift in the investment narrative. The company's future hinges on regulatory advancements for REZZAYO and successful navigation of reimbursement landscapes for its core products.
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And Phase III Results
CorMedix Inc. (CRMD) reported strong first-quarter 2026 results, with revenue of US$127.43 million and net income of US$38.6 million, prompting them to raise their full-year 2026 net revenue guidance to US$325 million to US$345 million. This updated guidance, coupled with positive Phase III results for REZZAYO and progress in other pipeline programs, may significantly alter the investment outlook for the company. Investors are now scrutinizing how these developments could reshape CorMedix's risk-reward profile and future growth trajectory.
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
CorMedix (CRMD) reported first-quarter 2026 diluted earnings of 43 cents per share, surpassing the Zacks Consensus Estimate, with net revenue of $127.4 million, significantly exceeding expectations. The strong performance was driven by DefenCath sales and the contribution from the Melinta portfolio acquisition. Following these positive results, management raised its full-year 2026 net revenue and adjusted EBITDA guidance.
Deep Track (CRMD) files Schedule 13G/A reporting 7.94% ownership
Deep Track-affiliated entities have filed a Schedule 13G/A with the SEC, disclosing a 7.94% beneficial ownership in CorMedix Inc. (CRMD), totaling 6,274,076 shares. The filing indicates shared voting and dispositive power among Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin. This passive investment is based on CorMedix's 79,050,395 outstanding shares as of March 2, 2026.
CorMedix Inc. (NASDAQ:CRMD) Q1 2026 Earnings Call Transcript
CorMedix Inc. reported strong first-quarter 2026 results, with net revenue of $127.4 million and adjusted EBITDA of $70 million, driven by DefenCath utilization and the acquired Melinta portfolio. The company raised its full-year 2026 financial guidance for net revenue to $325 million-$345 million and adjusted EBITDA to $115 million-$135 million, alongside increased DefenCath guidance to $175 million-$195 million. Furthermore, CorMedix announced positive preliminary top-line results from the ReSPECT study for REZZAYO in invasive fungal disease prophylaxis, with plans for an sNDA submission in the second half of 2026.
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
CorMedix Therapeutics announced its participation in two upcoming investor conferences: the RBC Capital Markets Global Healthcare Conference and the Jefferies Global Healthcare Conference. Management will engage in fireside chats and investor meetings to discuss the company's focus on developing and commercializing therapeutic products for life-threatening conditions in the US. Specific dates and webcast details for both events have been provided.
CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised
CorMedix Inc. (NASDAQ: CRMD) saw its stock jump after reporting strong first-quarter results, driven by high utilization of DefenCath and contributions from the Melinta portfolio acquisition. The company exceeded revenue and earnings consensus, leading to an increase in its full-year 2026 revenue and adjusted EBITDA guidance. CorMedix is also advancing pipeline programs, including a supplemental New Drug Application for REZZAYO and a Phase 3 study for its taurolidine/heparin catheter lock solution.
Cormedix Earnings Call Highlights Growth, Raises Outlook
Cormedix Inc. reported strong Q1 2026 financial results, with significant revenue and EBITDA growth driven by DefenCath and the Melinta acquisition. The company raised its full-year 2026 outlook for net revenue and adjusted EBITDA, signaling confidence in sustained demand and portfolio performance. However, potential challenges include the upcoming sunset of the TDAPA reimbursement for DefenCath, near-term inventory adjustments, and a delayed timeline for the NUTRI-GAURD TPN Phase III program.
CorMedix Inc. Stock 12‑Month Price Target Cut to $14.86, Implies 98% Upside
CorMedix Inc.'s average 12-month price target has been lowered by analysts from $15 to $14.86, with a range of $13 to $19 per share. This updated target suggests a potential upside of approximately 98% based on the May 13 closing price. The consensus rating from all 7 covering analysts remains a "Buy."
CRMD Stock Soared 18% Today – Here’s What Fueled CorMedix’s Triple-Digit Q1 Revenue Surge
CorMedix (CRMD) shares surged over 18% after the company reported strong first-quarter results, with revenue reaching $127.4 million, significantly exceeding Wall Street's expectations. The impressive growth was largely driven by DefenCath sales, prompting CorMedix to raise its full-year 2026 revenue and adjusted EBITDA guidance. Retail sentiment on Stocktwits also shifted to bullish following the positive news.
Cormedix Q1 2026 Earnings Call Transcript
Cormedix (NASDAQ: CRMD) reported strong first-quarter 2026 results, with net revenue of $127.4 million and adjusted EBITDA of $70 million, both exceeding expectations. The company raised its full-year net revenue guidance to $325-$345 million and adjusted EBITDA guidance to $115-$135 million, driven by robust performance and market demand for Defencath. Cormedix is also preparing for the potential commercial launch of Rizzeo in 2027 following positive preliminary results from the Respect Study, with an FDA submission anticipated in the second half of 2026.
CorMedix earnings missed by $0.02, revenue topped estimates
CorMedix reported first-quarter EPS of $0.430, missing analyst estimates by $0.02, but its revenue of $127.43M successfully topped the consensus estimate of $105.02M. The company also provided a positive FY 2026 revenue guidance, projecting between $325.000M and $345.000M, against an analyst consensus of $308.200M. CorMedix stock has shown an "excellent performance" financial health score according to InvestingPro.
CorMedix (CRMD) surges Q1 2026 revenue and hikes full-year guidance
CorMedix Inc. (CRMD) reported robust first-quarter 2026 financial results, with net revenue reaching $127.4 million and net income of $38.6 million, significantly exceeding prior year figures. The strong performance was driven by DefenCath sales and contributions from the acquired Melinta portfolio, leading the company to raise its full-year 2026 net revenue guidance to $325–$345 million and adjusted EBITDA guidance to $115–$135 million. Additionally, CorMedix announced positive Phase III topline results for REZZAYO and progress in other late-stage clinical trials.
CorMedix: Q1 Earnings Snapshot
CorMedix Inc. (CRMD) reported earnings of $38.6 million for its first quarter, translating to a net income of 43 cents per share. The pharmaceutical and medical device company, based in Parsippany, New Jersey, also posted revenues of $127.4 million for the period.
[10-Q] CorMedix Inc. Quarterly Earnings Report
CorMedix Inc. has filed its Quarterly Report (10-Q) for the period ended March 31, 2026, reporting a significant increase in total revenue to $127.4 million, up 226% from the prior year, largely due to the acquisition of Melinta and strong demand for DefenCath. The company recorded a net income of $38.6 million and detailed changes in its financial position, including operating expenses, liquidity, and ongoing litigation. CorMedix also highlighted the positive Phase III results for REZZAYO and discussed the impact of new tariffs on APIs and its strategy for cost optimization and onshoring manufacturing.
CorMedix Therapeutics reports Q1 2026: $127.4M revenue, $38.6M net income, $70.0M adjusted EBITDA
CorMedix Therapeutics reported strong first-quarter 2026 results, with net revenue reaching $127.4 million and net income at $38.6 million. The company's adjusted EBITDA was $70.0 million, and diluted EPS stood at $0.43. Following these positive outcomes, CorMedix raised its full-year 2026 revenue guidance to $325–$345 million and adjusted EBITDA guidance to $115–$135 million.
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
CorMedix Therapeutics reported strong first-quarter 2026 financial results, with net revenue of $127.4 million and adjusted EBITDA of $70.0 million, leading to an increase in their full-year 2026 guidance. The company saw significant contributions from DefenCath sales and the acquired Melinta portfolio, while also advancing its REZZAYO clinical trial for prophylaxis of invasive fungal diseases and a Phase 3 study for DefenCath in TPN patients. Joseph Todisco, Chairman & CEO, highlighted the strong momentum, profitability, and strategic pipeline advancements.
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Cormedix Therapeutics announced strong first-quarter 2026 financial results, reporting $127.4 million in net revenue and $38.6 million in net income, with Adjusted EBITDA reaching $70.0 million. The company's stock, CRMD, saw a significant surge following these positive earnings and increased guidance. Additionally, CRMD appears in several ChartMill screener lists, including Undervalued Stocks, High Free Cash Flow Stocks, Fastest Growing Stocks, and Revenue Growth Leaders, indicating robust financial health and growth prospects.
CorMedix Q1 2026 earnings preview
This article provides an earnings preview for CorMedix's Q1 2026 financial results. It briefly indicates that financial news is expected for the company.
Earnings Preview: CorMedix to Report Financial Results Pre-market on May 14
CorMedix (NASDAQ:CRMD) is scheduled to announce its Q1 2026 earnings pre-market on Tuesday, May 14. Analysts expect the company to report an EPS of -$0.10 and revenue of $0.18 million. The company has a history of beating EPS estimates and matching revenue estimates in recent quarters.
Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance
This article reports on Cormedix stock soaring pre-market following an earnings beat and increased full-year guidance. The company announced positive financial results, leading to a significant jump in its stock price.
CorMedix (Nasdaq:CRMD) - Stock Analysis
This Simply Wall St analysis provides an in-depth stock report for CorMedix (CRMD), a biopharmaceutical company focusing on therapeutic products for life-threatening diseases. The report details the company's valuation, future growth prospects, past performance, financial health, and recent news, including product approvals and financial guidance. It highlights CRMD's key products like DefenCath and REZZAYO, along with recent acquisition activities and analyst insights on its stock performance and future potential.
CORMEDIX THERAPEUTICS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 14, 2026
CORMEDIX Therapeutics, Inc. (CMDX) announced it will release its first-quarter 2026 financial results on May 14, 2026. The company will also host a conference call and webcast on the same day to provide a corporate update. This event will allow stakeholders to review financial performance and receive updates on company operations.
CorMedix Inc (NASDAQ:CRMD) Receives Consensus Rating of "Moderate Buy" from Analysts
CorMedix Inc (NASDAQ:CRMD) has been rated a "Moderate Buy" by analysts, with an average one-year price target of $15.00. This comes despite a recent EPS miss, though revenue saw a significant 312% year-over-year increase. The company's board has also approved a $75 million stock buyback, suggesting management believes the stock is undervalued.
CorMedix Therapeutics to Report First Quarter 2026
CorMedix Therapeutics announced it will report its first quarter 2026 financial results and provide a corporate update on Thursday, May 14, 2026, before market open. The company will also host a conference call at 8:30 AM ET on the same day. CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening conditions in the U.S.
What CorMedix says before the bell May 14: earnings and update
CorMedix (Nasdaq: CRMD) is scheduled to report its first-quarter 2026 financial results before market open on May 14, 2026. Following the earnings release, the company will host a corporate update conference call at 8:30 AM Eastern Time to discuss its performance and provide further updates. This announcement aligns with previous patterns of earnings date releases causing minor positive stock movements.
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
CorMedix Therapeutics announced it will report its first-quarter financial results for the period ended March 31, 2026, before market open on Thursday, May 14, 2026. The biopharmaceutical company will also host a corporate update conference call at 8:30 AM Eastern Time on the same day. CorMedix focuses on developing and commercializing therapeutic products for life-threatening conditions.
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance
CorMedix Inc. announced strong financial results for Q4 and full-year 2025, with Q4 net revenue of $128.6 million and net income of $14.0 million. The biopharmaceutical company reaffirmed its 2026 revenue guidance between $300 million and $320 million, and adjusted EBITDA between $100 million and $125 million, supported by significant DefenCath sales and its acquired Melinta portfolio. Analysts see considerable upside, with price targets ranging from $13 to $18, and the company has also authorized a $75 million share repurchase program.
[ARS] CorMedix Inc. SEC Filing
This article announces an SEC filing by CorMedix Inc. (CRMD) of Form ARS on April 29, 2026, at 04:20 PM. The filing is categorized as having a low impact and neutral sentiment. The article also provides an overview of CRMD's stock data, recent news, and other SEC filings.
CorMedix (CRMD) posts 2025 profit, seeks approval of key charter and governance changes
CorMedix (CRMD) is seeking stockholder approval for nine proposals at its June 23, 2026 annual meeting, following a strong financial performance in 2025 with $311.7 million in revenue and $163.0 million in net income. Key proposals include ratifying historical preferred stock amendments, technical charter clean-ups, establishing class-based voting for preferred shares, designating exclusive forums for certain legal claims, and expanding officer exculpation in line with Delaware law. These governance changes aim to enhance efficiency and reduce administrative burdens.
Positive REZZAYO Phase III Prophylaxis Data Might Change The Case For Investing In CorMedix (CRMD)
CorMedix (CRMD) announced positive Phase III ReSPECT trial results for REZZAYO prophylaxis for preventing invasive fungal diseases. This data supports a potential label expansion for REZZAYO and strengthens CorMedix's investment narrative, especially concerning its 2026 revenue guidance. The article suggests this news may influence how analysts and investors evaluate the company's future performance and ongoing risks related to pricing and market adoption.
Positive REZZAYO Phase III Prophylaxis Data Might Change The Case For Investing In CorMedix (CRMD)
CorMedix's investment case is strengthened by positive Phase III results for REZZAYO prophylaxis, which showed non-inferiority and a favorable safety profile for preventing invasive fungal diseases in stem cell transplant patients. This data supports a potential label expansion for REZZAYO, reinforcing CorMedix's near-term revenue guidance of US$300-320 million for 2026 and influencing its long-term financial forecasts, including a projected fair value of $14.57 per share. The company's future success hinges on execution of pricing, market uptake, and integration following the Melinta acquisition.
H.C. Wainwright reiterates CorMedix stock rating on trial results By Investing.com
H.C. Wainwright reiterated a Buy rating and a $13.00 price target for CorMedix Inc. following positive Phase 3 trial results for its drug candidate REZZAYO, which achieved non-inferiority in fungal-free survival with a favorable safety profile. Other analysts like RBC Capital, Citizens, and Truist Securities also maintain positive outlooks, while Leerink Partners adjusted its target due to revised operating expense projections. The firm believes CorMedix is trading near a valuation floor with pipeline upside potential.
H.C. Wainwright reiterates CorMedix stock rating on trial results
H.C. Wainwright reiterated a Buy rating and $13.00 price target on CorMedix Inc. (NASDAQ:CRMD) following positive Phase 3 trial results for its drug candidate REZZAYO in prophylaxis of invasive fungal disease. The drug achieved its primary endpoint of non-inferiority with a more favorable safety profile. Other analysts like RBC Capital and Citizens also maintained positive ratings, while Leerink Partners adjusted its price target due to revised operating expense projections.
CorMedix stock rating maintained at outperform by Citizens
Citizens has reiterated an "Outperform" rating on CorMedix Inc. (NASDAQ:CRMD) and maintained a $19.00 price target, citing significant upside potential from its current trading price of $7.82. The positive assessment follows promising Phase 3 results for REZZAYO in preventing fungal infections in blood and marrow transplant patients. Despite a recent earnings per share miss, the company boasts impressive 93% gross profit margins, and analysts including RBC Capital and Truist Securities remain optimistic about its commercialization prospects.
Positive REZZAYO Phase III Prophylaxis Data Might Change The Case For Investing In CorMedix (CRMD)
CorMedix (CRMD) recently announced positive Phase III topline results for its REZZAYO prophylaxis, showing non-inferiority for preventing invasive fungal diseases in transplant patients. This strengthens the case for a label expansion into a high-risk setting and supports the company's near-term revenue guidance of US$300-US$320 million for 2026. The results, particularly the once-weekly dosing, could significantly impact the company's investment narrative, though risks related to pricing, uptake, and integration post-Melinta acquisition remain.
RBC Capital raises CorMedix stock price target on phase III data
RBC Capital has raised its price target for CorMedix Inc. (NASDAQ: CRMD) shares to $14.00 from $13.00, maintaining an Outperform rating, following positive Phase III trial results for Rezzayo in preventing fungal infections. The firm noted Rezzayo's competitive profile and potential for broad-spectrum activity, favorable tolerability, and fewer discontinuations. Despite an EPS shortfall in Q4 2025, CorMedix's impressive 93% gross profit margin and expected revenue potential support RBC Capital's optimistic outlook.
CorMedix nears an 11-month low after earnings miss
CorMedix stock (CRMD) neared an 11-month low after reporting a significant earnings miss. The company reported a Q4 loss of $0.20 per share, worse than the expected $0.18 loss, and annual revenue of $29.8 million, falling short of the $33.5 million consensus. This financial underperformance for the year appears to be the primary driver of the stock's downturn.
RBC Raises Price Target on CorMedix to $14 From $13, Keeps Outperform, Speculative Risk
RBC has increased its price target for CorMedix (CRMD) to $14 from $13, maintaining an "Outperform" rating with a "Speculative Risk" designation. This adjustment reflects RBC's continued positive outlook on the biopharmaceutical company which focuses on treatments for life-threatening conditions. The article also notes that CorMedix's product, Rezzayo, recently met its primary endpoint in a study for the prevention of invasive fungal diseases.
RBC Capital raises CorMedix stock price target on phase III data
RBC Capital has increased its price target for CorMedix Inc. (NASDAQ:CRMD) to $14.00 from $13.00, maintaining an Outperform rating after the company announced positive Phase III results for Rezzayo. The firm highlighted Rezzayo's potential to generate substantial revenues and noted that CorMedix shares appear undervalued according to InvestingPro analysis, despite a recent earnings per share shortfall. Other analysts like Leerink Partners and Truist Securities have also adjusted their targets and ratings, indicating a varied outlook for the company.
CorMedix nears an 11-month low after earnings miss
CorMedix is nearing an 11-month low following an earnings miss. The company's stock performance reflects investor sentiment after the weaker-than-expected financial results. This downturn could lead to increased scrutiny on its future financial outlook and operational strategies.
CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study
CorMedix (NASDAQ: CRMD) shares rose following positive topline results from its Phase 3 ReSPECT trial for REZZAYO, a prophylaxis for invasive fungal diseases. The study met its primary endpoint, demonstrating non-inferiority to standard treatments with comparable efficacy and a favorable safety profile. The company anticipates submitting a supplemental New Drug Application (sNDA) in the second half of 2026 and estimates a potential U.S. market exceeding $2 billion for REZZAYO.
Phase III ReSPECT success boosts CorMedix (CRMD) REZZAYO prophylaxis plans
CorMedix announced positive Phase III ReSPECT trial results for REZZAYO, which met its primary endpoint for fungal-free survival in adult allogeneic stem cell transplant patients. The company estimates a potential U.S. prophylaxis market exceeding $2 billion and plans to submit a supplemental New Drug Application (sNDA) in the second half of 2026 to expand REZZAYO's indication. Favorable safety and efficacy against various fungal pathogens were observed, supported by orphan drug and patent exclusivity through 2035 and 2038, respectively.
Weekly REZZAYO matched standard care for transplant patients
CorMedix announced positive Phase III topline results for its drug REZZAYO, which demonstrated non-inferiority to standard antimicrobial regimens in preventing invasive fungal diseases in allogeneic HSCT patients. The ReSPECT trial showed 60.7% fungal-free survival for REZZAYO compared to 59.0% for the standard treatment, along with a favorable safety profile. CorMedix plans a pre-NDA meeting and a supplemental New Drug Application submission to the FDA in the second half of 2026.
CorMedix Therapeutics Announces Positive Topline Results
CorMedix Therapeutics announced positive topline results from its Phase III ReSPECT trial for REZZAYO (rezafungin for injection), showing non-inferiority against standard antimicrobial regimens in preventing invasive fungal diseases in allogeneic HSCT patients. The study met its primary endpoint for fungal-free survival at Day 90 and demonstrated a favorable safety profile with fewer toxicity-related discontinuations and drug-drug interactions. CorMedix plans to submit a supplemental New Drug Application (sNDA) to the FDA in the second half of 2026, aiming to expand REZZAYO's indication, with an estimated U.S. market potential exceeding $2 billion for prophylaxis.
Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance
The article from MSN was empty and did not contain any content about Cormedix's earnings or guidance. Therefore, no summary can be provided.
